ReviewsMechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Under an Elsevier user license
open archive
Key words
epidermal growth factor receptor (EGFR)
lung cancer
tyrosine kinase inhibitor (TKI)
acquired resistance
T790M
Cited by (0)
- †
D. Westover and J. Zugazagoitia authors contributed equally to this work.
- *
Professor Vansteenkiste has acted as a consultant for Merck-Serono, GSK-Bio, and Lilly Oncology.
Copyright © 2018 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.